Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

RA Prevention: A Trial of Methotrexate Vs. Placebo in Patients with Undifferentiated Arthritis

Arthritis & Rheumatology  |  May 2, 2017

Disease outcomes in rheumatoid arthritis (RA) have improved dramatically since the introduction of biologic agents and improved treatment strategies. Nevertheless, the majority of patients still require prolonged, if not lifelong, therapy. Therefore, the ultimate goal would be to prevent RA.

Before RA is diagnosed, many patients present with undifferentiated arthritis (UA) or arthralgia. Clinical trials in patients presenting with arthralgia are still scarce, but several trials have evaluated whether intervention with disease-modifying anti-rheumatic drugs (DMARDs) in UA is effective in preventing progression to classifiable RA. The results of these trials were mixed, but none showed that RA development could be prevented by early intervention with DMARDs. The finding that there was no improved outcome if disease-modifying treatment was started in the phase of UA is surprising and is in contrast to results of multiple observational studies that showed the benefit of early intervention in RA. Altogether, this raises the question of whether the principle of “the earlier the better” does not apply to the phase of UA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A model for predicting risk of RA development in UA patients is now well established and widely replicated and offers the opportunity to identify those UA patients who have a high risk of developing RA. This model, therefore, enables postrandomization exclusion of patients without a high risk of RA. Therefore, in the present study, the researchers aimed to analyze the effect of a one-year course of methotrexate (MTX) in high-risk UA patients by reanalyzing the Probable Rheumatoid Arthritis: Methotrexate vs. Placebo Treatment (PROMPT) trial after post-randomization exclusion of patients without a high risk of developing RA.

Methods: A validated prediction model was used to determine the risk of RA in all patients included in the PROMPT trial. Patients with a prediction score of ≥8 (positive predictive value of ≥84% for developing RA) were considered to have a high risk of developing RA. The effect of a one-year course of MTX during five years of follow-up was reinvestigated in these patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Twenty-two of the 110 patients in the PROMPT trial had a high risk of RA at baseline. In the MTX arm, six of 11 patients (55%) developed RA, compared with 11 of 11 patients (100%) in the placebo arm (P=0.011). Time to RA development was longer in the MTX arm than in the placebo arm (median 22.5 months vs. three months; P<0.001). Drug-free remission was achieved by four of 11 patients (36%) in the MTX arm compared with 0 of 11 patients (0%) in the placebo arm (P=0.031). These beneficial effects of MTX were observed both in anti-citrullinated protein antibody (ACPA) positive and in ACPA-negative UA patients with a high risk of RA, but not in UA patients without a high risk of RA. In retrospect, 43 of 110 patients fulfilled the ACR/EULAR 2010 classification criteria for RA at baseline. In addition, beneficial effects were observed only in patients with a high prediction score.

Conclusion: A one-year course of MTX delayed and prevented RA development in high-risk UA patients. This emphasizes the importance of adequate risk prediction in trials that aim to prevent RA.

Read the full article.

Excerpted and adapted from:

Burgers LE, Allaart CF, Huizinga TWJ, et al. Clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: Using a trial of methotrexate versus placebo in patients with undifferentiated arthritis as an example. Arthritis Rheumatol. 2017 May;69(5):926–931.

Page: 1 2 | Multi-Page
Share: 

Filed under:Drug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyDisease-modifying antirheumatic drugs (DMARDs)MethotrexateResearchRheumatoid Arthritis (RA)undifferentiated arthritis

Related Articles

    A&R Abstracts: Methotrexate

    November 1, 2011

    For further reading

    Reading Rheum

    April 1, 2009

    Handpicked Reviews of Contemporary Literature

    Pursue Remission

    November 1, 2007

    Disease remission should be the goal for all rheumatologists treating childhood arthritis

    Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

    August 16, 2019

    Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences